INSM INSMED Inc
Pharmaceutical Preparations · Nasdaq · SEC CIK 1104506 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY240.0%
TTM net income YoY48.8%
TTM EPS YoY54.6%
Revenue 3-yr CAGR75.6%
Net income 3-yr CAGR—
Margins
Gross margin84.4%
Operating margin-37.1%
Net margin-39.9%
FCF margin-41.3%
EBITDA margin-36.3%
Returns
ROE-72.5%
ROA-26.4%
ROIC (approx.)-43.8%
Asset turnover0.66x
Leverage & solvency
Liabilities / assets67.4%
Debt / equity0.76x
Current ratio2.86x
Interest coverage-6.93x
Cash quality & payout
Operating cash flow / net income0.98x
Accruals ratio-0.4%
Payout ratio—
Capex / revenue2.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $524.43M | $425.49M | $305.96M | $263.84M | $142.34M | $107.42M | $92.82M | $104.44M |
| Cost of revenue | $78.22M | $67.21M | $47.42M | $44.22M | $29.36M | $28.07M | $21.28M | $26.15M |
| Gross profit | $446.21M | $358.27M | $258.54M | $219.62M | $112.98M | $79.34M | $71.55M | $78.29M |
| R&D expense | $269.96M | $210.03M | $209.49M | $254.91M | $186.41M | $177.19M | $152.58M | $179.73M |
| SG&A expense | $253.03M | $247.47M | $247.26M | $212.48M | $186.38M | $154.76M | $147.54M | $142.51M |
| Operating income | -$89.37M | -$1.55M | -$153.32M | -$319.75M | -$366.00M | -$312.88M | -$248.14M | -$230.41M |
| Interest expense | $20.41M | $20.27M | $20.08M | $20.60M | $20.38M | $21.25M | $21.57M | $21.55M |
| Pretax income | -$97.65M | -$11.37M | -$162.10M | -$326.93M | -$368.70M | -$320.44M | -$255.67M | -$234.28M |
| Income tax | $2.67M | $1.87M | $1.47M | $1.55M | $1.32M | $1.24M | $912,000 | $1.27M |
| Net income | -$100.32M | -$13.24M | -$163.56M | -$328.49M | -$370.02M | -$321.69M | -$256.58M | -$235.55M |
| EBITDA | -$86.02M | $1.63M | -$150.39M | -$316.12M | -$363.55M | -$310.39M | -$246.26M | -$228.94M |
| EPS (basic) | -0.46 | -0.06 | -0.76 | — | -1.75 | -1.70 | -1.42 | — |
| EPS (diluted) | -0.46 | -0.06 | -0.76 | — | -1.75 | -1.70 | -1.42 | — |
| Weighted avg. shares (diluted) | 218.79M | 217.35M | 215.47M | — | 211.76M | 189.30M | 180.86M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $396.56M | $544.76M | $582.19M | $510.44M | $334.76M | $1.28B | $403.25M | $555.03M |
| Short-term investments | $750.06M | $615.55M | $641.33M | $919.60M | $1.35B | $572.44M | $796.20M | $878.80M |
| Receivables | $259.27M | $215.32M | $178.56M | $140.86M | $65.26M | $55.03M | $47.75M | $52.01M |
| Inventory | $163.95M | $142.38M | $132.91M | $132.07M | $120.97M | $107.61M | $100.71M | $98.58M |
| Current assets | $1.71B | $1.63B | $1.61B | $1.79B | $1.93B | $2.08B | $1.40B | $1.62B |
| PP&E, net | $108.34M | $107.22M | $102.85M | $102.94M | $89.67M | $90.00M | $88.36M | $80.05M |
| Goodwill | $136.11M | $136.11M | $136.11M | $136.11M | $136.11M | $136.11M | $136.11M | $136.11M |
| Intangibles | $138.44M | $93.49M | $95.57M | $97.65M | $84.59M | $56.13M | $57.39M | $58.65M |
| Total assets | $2.23B | $2.10B | $2.08B | $2.26B | $2.36B | $2.48B | $1.80B | $2.03B |
| Current liabilities | $596.58M | $438.74M | $361.01M | $468.87M | $417.21M | $311.68M | $239.23M | $297.53M |
| Short-term debt | $10.23M | — | — | $0 | — | — | — | — |
| Long-term debt | $544.86M | $543.51M | $542.22M | $540.96M | $539.72M | $538.51M | $1.11B | $1.10B |
| Total debt | $555.09M | $543.51M | $542.22M | $540.96M | $539.72M | $538.51M | $1.11B | $1.10B |
| Total liabilities | $1.50B | $1.35B | $1.37B | $1.53B | $1.42B | $1.23B | $1.70B | $1.74B |
| Shareholders' equity | $726.21M | $757.49M | $704.85M | $738.98M | $945.57M | $1.25B | $99.16M | $285.38M |
| Net debt | $158.53M | -$1.25M | -$39.97M | $30.52M | $204.96M | -$745.82M | $701.82M | $548.35M |
| Shares outstanding | 219.32M | 218.28M | 216.52M | 214.26M | 212.58M | 211.11M | 181.90M | 179.38M |
| Cash flow statement | ||||||||
| Operating cash flow | -$36.46M | -$88.83M | -$222.74M | -$247.60M | -$219.76M | -$205.57M | -$262.09M | -$195.98M |
| Capital expenditure | $5.62M | $6.26M | $3.48M | $16.59M | $2.42M | $3.48M | $10.07M | $6.77M |
| Free cash flow | -$42.09M | -$95.09M | -$226.22M | -$264.19M | -$222.18M | -$209.05M | -$272.16M | -$202.75M |
| Investing cash flow | -$135.65M | $24.51M | $265.52M | $389.41M | -$762.23M | $227.84M | $80.41M | $131.76M |
| Financing cash flow | $23.64M | $27.18M | $29.51M | $33.86M | $33.41M | $857.81M | $29.00M | $159.31M |
| Depreciation & amortization | $3.35M | $3.18M | $2.93M | $3.62M | $2.46M | $2.48M | $1.88M | $1.48M |
| Stock-based compensation | $41.22M | $41.25M | $45.75M | $39.04M | $31.43M | $42.98M | $39.26M | $26.55M |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.